[Restoration of ejaculate quality following androgen replacement and combined therapy for hypogonadism].

Sperm concentration showed statistically significant negative dynamics in the androgen replacement therapy (AZT) group following stimulating gonadotropin therapy.

• The AZT group included 19 men who had received androgen replacement therapy for more than 5 years before stimulating gonadotropin therapy.
• Sperm concentration in the AZT group demonstrated 'statistically significant negative dynamics.'
• The basic level of statistical significance was p<0.05.
• Patients were evaluated at The National Medical Research Center for Endocrinology.

Sperm concentration in the combination therapy (AZT/HG) group did not show statistically significant differences in dynamics following stimulating gonadotropin therapy.

• The AZT/HG group included 34 men who received course combination therapy with testosterone and chorionic gonadotropin for more than 5 years.
• There were 'no statistically significant differences in the dynamics of sperm concentration' in the AZT/HG group.
• Statistically significant differences in the value of sperm concentration change were revealed between the two groups.
• Groups were comparable in age, BMI, duration of therapy, type of testosterone preparation, and etiology of hypogonadism.

Both the AZT and AZT/HG groups showed statistically significant negative dynamics for sperm motility and morphology following stimulating gonadotropin therapy.

• Statistically significant negative dynamics for sperm motility and morphology were observed in both groups.
• There were no statistically significant differences in the value of changes in motility and sperm morphology between the two study groups.
• Neither method showed satisfactory results for the restoration of sperm motility and morphology.
• The total study population was 53 men (AZT n=19; AZT/HG n=34).

Combined testosterone and chorionic gonadotropin therapy produced better sperm concentration restoration outcomes compared to androgen replacement therapy alone.

• Course combination therapy with testosterone and chorionic gonadotropin 'is characterized by better results for sperm concentration restoration compared with androgenic replacement therapy.'
• This was an observational prospective study with more than 5 years of therapy duration before stimulating gonadotropin therapy.
• The study aimed to optimize androgen replacement therapy for male hypogonadism to improve reproductive prospects.